secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001213900-23-064577
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Q2 net loss narrows; Phase 3 MDD trials on track for 2024
-----------------------------------------------------------------

- Net loss $25.3M ($0.84/share) vs $39.9M ($1.33) in Q2 2022; R&D expense down to $13.7M from $30.9M.
- Cash and short-term investments $118.5M at June 30; company says sufficiently funded for Phase 3 readouts in 2024.
- Phase 3 Reliance II (302) enrollment ongoing; Relight (304) screening started; both expected to complete in 2024.
- One-year open-label safety study (Reliance-OLS) completed; data expected later in the current quarter.
- Human abuse potential data for REL-1017 published in peer-reviewed Translational Psychiatry.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023064577/0001213900-23-064577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023064577/ea183083-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-064577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer